Karen Daniel
Overview
Explore the profile of Karen Daniel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
96
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Daneshmand S, Kamat A, Shore N, Meeks J, Galsky M, Jacob J, et al.
Urol Oncol
. 2025 Jan;
PMID: 39818460
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review...
2.
Cima M, Lee H, Daniel K, Tanenbaum L, Mantzavinou A, Spencer K, et al.
J Control Release
. 2014 May;
190:157-71.
PMID: 24798478
Drug design is built on the concept that key molecular targets of disease are isolated in the diseased tissue. Systemic drug administration would be sufficient for targeting in such a...
3.
Nickel J, Jain P, Shore N, Anderson J, Giesing D, Lee H, et al.
Sci Transl Med
. 2012 Jul;
4(143):143ra100.
PMID: 22814850
Limited treatment options exist for patients who suffer from a painful bladder condition known as interstitial cystitis/bladder pain syndrome (IC/BPS). Whether given systemically (orally) or by short-duration (1 to 2...
4.
Wagner H, Pizzimenti J, Daniel K, Pandya N, Hardigan P
Diabetes Educ
. 2008 Feb;
34(1):84-9.
PMID: 18267994
Purpose: The purpose of this study is to compare the efficacy of usual care to an intervention emphasizing patient education targeted at a multicultural adult patient population with diabetes seeking...
5.
Staples M, Daniel K, Cima M, Langer R
Pharm Res
. 2006 May;
23(5):847-63.
PMID: 16715375
Micro- and nano-electromechanical systems (MEMS and NEMS)-based drug delivery devices have become commercially-feasible due to converging technologies and regulatory accommodation. The FDA Office of Combination Products coordinates review of innovative...
6.
7.